Notice Type
Departmental
Notice Title

Renewal of Provisional Consent to the Distribution of Medicines

Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicines set out in the Schedule hereto:

Schedule

Product: 0.9% Sodium Chloride Injection
Active Ingredient: Sodium chloride 0.9%w/v
Dosage Form: Solution for infusion
New Zealand Sponsor: Baxter Healthcare Limited
Manufacturer: Baxter S.A. de C.V., Jiutepec, Mexico

Note: This renewed consent is valid for two years from 9 July 2022.

Product: Clopine
Active Ingredient: Clozapine 25mg
Dosage Form: Tablet
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Douglas Manufacturing Limited, Auckland, New Zealand

Note: This consent is given subject to the following conditions:

  1. The medicine may only be prescribed by:
    • A medical practitioner who is vocationally registered by the Medical Council of New Zealand in the scope of practice of psychiatry (hereinafter referred to as a Psychiatrist)
    • A medical practitioner or nurse practitioner who is prescribing under the supervision of a Psychiatrist
    • A medical practitioner who is registered by the Medical Council of New Zealand in a general scope of practice provided the medical practitioner is prescribing clozapine for a patient whose illness is being well controlled by clozapine and the prescribing decision is taken in collaboration with, or following consultation with, a Community Mental Health Team
  2. Persons prescribing the medicine must comply with appropriate local treatment guidelines.
  3. The medicine must be dispensed in accordance with appropriate local dispensing guidelines.
  4. Sale or marketing of this medicine may only occur if the sponsor has an appropriate blood monitoring and patient record database in place.

Note: This renewed consent is valid for two years from 10 July 2022.

Product: Clopine
Active Ingredient: Clozapine 50mg
Dosage Form: Tablet
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Douglas Manufacturing Limited, Auckland, New Zealand

Note: This consent is given subject to the following conditions:

  1. The medicine may only be prescribed by:
    • A medical practitioner who is vocationally registered by the Medical Council of New Zealand in the scope of practice of psychiatry (hereinafter referred to as a Psychiatrist)
    • A medical practitioner or nurse practitioner who is prescribing under the supervision of a Psychiatrist
    • A medical practitioner who is registered by the Medical Council of New Zealand in a general scope of practice provided the medical practitioner is prescribing clozapine for a patient whose illness is being well controlled by clozapine and the prescribing decision is taken in collaboration with, or following consultation with, a Community Mental Health Team
  2. Persons prescribing the medicine must comply with appropriate local treatment guidelines.
  3. The medicine must be dispensed in accordance with appropriate local dispensing guidelines.
  4. Sale or marketing of this medicine may only occur if the sponsor has an appropriate blood monitoring and patient record database in place.

Note: This renewed consent is valid for two years from 10 July 2022.

Product: Clopine
Active Ingredient: Clozapine 100mg
Dosage Form: Tablet
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Douglas Manufacturing Limited, Auckland, New Zealand

Note: This consent is given subject to the following conditions:

  1. The medicine may only be prescribed by:
    • A medical practitioner who is vocationally registered by the Medical Council of New Zealand in the scope of practice of psychiatry (hereinafter referred to as a Psychiatrist)
    • A medical practitioner or nurse practitioner who is prescribing under the supervision of a Psychiatrist
    • A medical practitioner who is registered by the Medical Council of New Zealand in a general scope of practice provided the medical practitioner is prescribing clozapine for a patient whose illness is being well controlled by clozapine and the prescribing decision is taken in collaboration with, or following consultation with, a Community Mental Health Team
  2. Persons prescribing the medicine must comply with appropriate local treatment guidelines.
  3. The medicine must be dispensed in accordance with appropriate local dispensing guidelines.
  4. Sale or marketing of this medicine may only occur if the sponsor has an appropriate blood monitoring and patient record database in place.

Note: This renewed consent is valid for two years from 10 July 2022.

Product: Clopine
Active Ingredient: Clozapine 200mg
Dosage Form: Tablet
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer: Douglas Manufacturing Limited, Auckland, New Zealand

Note: This consent is given subject to the following conditions:

  1. The medicine may only be prescribed by:
    • A medical practitioner who is vocationally registered by the Medical Council of New Zealand in the scope of practice of psychiatry (hereinafter referred to as a Psychiatrist)
    • A medical practitioner or nurse practitioner who is prescribing under the supervision of a Psychiatrist
    • A medical practitioner who is registered by the Medical Council of New Zealand in a general scope of practice provided the medical practitioner is prescribing clozapine for a patient whose illness is being well controlled by clozapine and the prescribing decision is taken in collaboration with, or following consultation with, a Community Mental Health Team
  2. Persons prescribing the medicine must comply with appropriate local treatment guidelines.
  3. The medicine must be dispensed in accordance with appropriate local dispensing guidelines.
  4. Sale or marketing of this medicine may only occur if the sponsor has an appropriate blood monitoring and patient record database in place.

Note: This renewed consent is valid for two years from 10 July 2022.

Product: Clozaril
Active Ingredient: Clozapine 25mg
Dosage Form: Tablet
New Zealand Sponsor: Viatris Limited
Manufacturers: Madaus GmbH, Troisdorf, Germany
Novartis Saglik ve Gida Urunleri Sanayi ve Ticaret AS, Istanbul, Turkey
McDermott Laboratories Limited t/a Gerard Laboratories t/a Mylan Dublin, Dublin, Ireland

Note: This consent is given subject to the following conditions:

  1. The medicine may only be prescribed by:
    • A medical practitioner who is vocationally registered by the Medical Council of New Zealand in the scope of practice of psychiatry (hereinafter referred to as a Psychiatrist)
    • A medical practitioner or nurse practitioner who is prescribing under the supervision of a Psychiatrist
    • A medical practitioner who is registered by the Medical Council of New Zealand in a general scope of practice provided the medical practitioner is prescribing clozapine for a patient whose illness is being well controlled by clozapine and the prescribing decision is taken in collaboration with, or following consultation with, a Community Mental Health Team
  2. Persons prescribing the medicine must comply with appropriate local treatment guidelines.
  3. The medicine must be dispensed in accordance with appropriate local dispensing guidelines.
  4. Sale or marketing of this medicine may only occur if the sponsor has an appropriate blood monitoring and patient record database in place.

Note: This renewed consent is valid for two years from 10 July 2022.

Product: Clozaril
Active Ingredient: Clozapine 100mg
Dosage Form: Tablet
New Zealand Sponsor: Viatris Limited
Manufacturers: Madaus GmbH, Troisdorf, Germany
Novartis Saglik ve Gida Urunleri Sanayi ve Ticaret AS, Istanbul, Turkey
McDermott Laboratories Limited t/a Gerard Laboratories t/a Mylan Dublin, Dublin, Ireland

Note: This consent is given subject to the following conditions:

  1. The medicine may only be prescribed by:
    • A medical practitioner who is vocationally registered by the Medical Council of New Zealand in the scope of practice of psychiatry (hereinafter referred to as a Psychiatrist)
    • A medical practitioner or nurse practitioner who is prescribing under the supervision of a Psychiatrist
    • A medical practitioner who is registered by the Medical Council of New Zealand in a general scope of practice provided the medical practitioner is prescribing clozapine for a patient whose illness is being well controlled by clozapine and the prescribing decision is taken in collaboration with, or following consultation with, a Community Mental Health Team
  2. Persons prescribing the medicine must comply with appropriate local treatment guidelines.
  3. The medicine must be dispensed in accordance with appropriate local dispensing guidelines.
  4. Sale or marketing of this medicine may only occur if the sponsor has an appropriate blood monitoring and patient record database in place.

Note: This renewed consent is valid for two years from 10 July 2022.

Dated this 6th day of July 2022.

CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).